-
12.14.2017 | CARB-X joint oversight committee updates
Ann Eakin appointed to the Joint Oversight Committee, replacing Michael Kurilla
-
11.07.2017 | CARB-X awards Seres Therapeutics $2.5M and possibly $3.1M more if certain milestones are met to develop a microbiome therapeutic to prevent serious bacterial infections and graft versus host disease in transplant patients
CARB-X is backing Seres Therapeutics Inc. (NASDAQ:MCRB) of Cambridge, MA, in the development of a promising pre-clinical microbiome therapeutic to prevent serious bacterial infections and graft versus host disease in patients following solid organ and allogeneic stem cell transplantation. The initial award provides Seres up to $2.5 million with the possibility of up to $3.1 million more if certain project milestones are achieved.
-
11.02.2017 | CARB-X awards up to $5.4M to Vedanta Biosciences to accelerate the development of a novel human microbiome-derived treatment for deadly C. difficile bacterial infections
CARB-X announced today that it has awarded Vedanta Biosciences of Cambridge, MA (an affiliate of PureTech Health, LSE: PRTC) up to $5.4M to support the development of a novel, human microbiome-derived treatment for the prevention of bacterial infections caused by C. difficile.
-
11.01.2017 | CARB-X backs Integrated Biotherapeutics to accelerate the development of a novel toxoid-based vaccine to prevent drug-resistant MRSA infections
CARB-X portfolio gains first vaccine project - a highly innovative approach to the prevention of life-threatening infections often contracted in hospitals CARB-X is awarding up to $168,000 to Integrated Biotherapeutics of Rockville, Maryland, with the possibility of up to $8.3 million more based on achievement of milestones, to develop a novel and innovative vaccine for the prevention of serious drug-resistant infections known as MRSA.
-
10.31.2017 | CARB-X awards Inhibrx up to $4.55M to accelerate the development of a novel antibody to treat Pseudomonas superbugs
CARB-X announced today that it has awarded Inhibrx $4.55M and potentially up to $6M to accelerate the development of a new antibody designed to prevent and treat infections caused by Pseudomonas, a difficult-to-treat family of Gram-negative bacterial pathogens often found in hospital and health-care settings.
-
10.26.2017 | CARB-X Executive Team and Joint Oversight Committee updates
Global Project Director Karen Gallant appointed to the Joint Oversight Committee, John Rex steps down as CARB-X Chief Strategy Officer
-
10.24.2017 | CARB-X awards Amicrobe $2.48M to accelerate the development of Amicidin-β topical antimicrobial
Scientific diversity of CARB-X portfolio boosted with Amicrobe's ground-breaking research on topically applied antimicrobials for use on infected tissue in surgical, emergency and post-disaster settings
-
10.12.2017 | CARB-X announces $3.8M award to Entasis Therapeutics to speed the development of Entasis’ non beta-lactam PBP inhibitor
CARB-X announced today an award worth $3.8 million to Entasis Therapeutics to accelerate the development of a new antibiotic class to treat serious drug-resistant Gram-negative bacterial infections.
-
09.05.2017 | CARB-X’s first year: A story of global achievement and progress
CARB-X's first year has been one of achievement and progress in the global fight against drug-resistant bacteria, with a growing pipeline of 18 promising research projects including 8 new classes of antibiotics to treat the most urgent superbugs.
-
07.25.2017 | CARB-X announces funding for global scientists racing to discover new antibiotics to treat superbugs
Scientists developing promising new antibiotics in India, Ireland, France, Switzerland, the US and UK are to share up to US$17.6m to speed treatments for the world's deadliest superbugs. A year since launching, the international partnership CARB-X today announces its second round of antibiotic research and development funding – alongside a call for greater global support.
-
03.30.2017 | CARB-X injects up to $48 million to accelerate first Powered by CARB-X portfolio of drug development projects to tackle antibiotic resistance
CARB-X announced today it is investing US$24 million immediately and up to $24 million in milestone-based additional payments over three years to help 11 biotech companies and research teams in the U.S. and U.K. accelerate the development of new life-saving antibacterials and diagnostics aimed at treating infections caused by the world's deadliest antibiotic-resistant bacteria.
Toggle navigation